In contrast to phospho-EGFR, EGFR expression in primary colon cancers has been shown to be an adverse prognostic marker in some (Lee et al, 2002; Resnick et al, 2004), but not other (McKay et al, 2002; Spano et al, 2005), studies and an evaluation of its prognostic effect using the FDA-approved antibody and methodology is lacking. This evidence concerns the gene EGFR and colonic neoplasm.